Early clinical improvement, not baseline traits, was associated with response to adjunctive lumateperone in MDD, though its ...

Negative symptoms of schizophrenia improved more with a digital therapeutic than with a control app, but durability and ...

For most patients, depression reflects the combined influence of biological vulnerability, symptom burden, functional ...

Specific phobia is among the most prevalent anxiety disorders in epidemiological surveys. 1 The DSM-5 classifies specific phobias into 5 subtypes: animal, natural environment, blo ...

Scott Thompson, PhD, discusses psychedelic research at CU Anschutz, real-world Colorado psilocybin outcomes, 5-HT2A ...

Conceptual issues, methodological issues, and findings related to long-term risk of dementia with ECT are discussed.

The strongest associations were observed for sister's postpartum psychosis, cyclothymia, schizoaffective disorder, and ...

In this webinar, Balwinder Singh, MD, and Raman Baweja, MD, describe emerging evidence on GLP-1 receptor agonists for ...

Findings from an analysis of 10 studies suggest lithium is effective in preventing postpartum recurrence of mood disorders.

Objective: Lumateperone is an FDA-approved atypical antipsychotic to treat schizophrenia, bipolar I or II depression, and major depressive disorder (MDD). Post hoc analyses of a randomized, phase 3, ...

A 66-year-old woman with no psychiatric history presented to the emergency department with several weeks of paranoid delusions regarding her finances, worsening isolation, uncontrollable anxiety, ...